India's pharmaceutical sector faces direct pressure from Trump administration tariff proposals. The CEO of Dr. Reddy's Laboratories, a major supplier of generic medications to U.S. markets, warned that new levies on imported drugs will push consumer prices higher and reduce access to affordable treatments.
Generic drugs account for roughly 90 percent of prescriptions filled in the United States but rely heavily on imports from India, which manufactures approximately 80 percent of active pharmaceutical ingredients used globally. Dr. Reddy's and competitors like Aurobindo Pharma and Lupin supply vast quantities of low-cost generics to American patients, holding down medication costs for millions.
Tariffs on these imports would disrupt this supply chain directly. Indian manufacturers cannot absorb the added costs without cutting margins to unsustainable levels. The practical result lands on patients and pharmacy benefit managers. Either generic prices rise, or companies exit the U.S. market entirely, creating shortages of essential treatments for chronic conditions like diabetes, hypertension, and infections.
The timing complicates matters. U.S. pharmaceutical companies like Johnson & Johnson and Pfizer source ingredients and finished drugs from India as well. A tariff regime that targets generic imports will force American drugmakers to choose between accepting higher costs or reshoring production at significantly higher expense. Neither scenario benefits consumers or the healthcare system.
Dr. Reddy's employs roughly 27,000 people globally with substantial operations in Hyderabad and other Indian cities. The company generated revenues exceeding $10 billion in recent fiscal years, with North America accounting for roughly 40 percent of sales. A tariff shock threatens both Dr. Reddy's profitability and its ability to sustain employment in India.
Policy experts flag a core tension. The Biden and Trump administrations both pledged to reduce prescription drug costs, but tariffs on generic ingredients work in the opposite direction. Generic drugs already function as the primary cost-control mechanism in American healthcare. Tariffs threaten to unwind years of progress on drug affordability.
The pharmaceutical supply chain runs through India by necessity, not choice. American generic manufacturers cannot operate without Indian suppliers. Any tariff strategy that ignores this dependency risks public backlash and potential price controls, creating political pressure Congress may struggle to contain.